Treeway, an Amyotrophic Lateral Sclerosis (ALS) R&D strategy-focused company, and Amarna Therapeutics have formed a collaboration to identify new therapeutic targets for the treatment of ALS.
The aim of the project is to screen for new targets that play a role in both the cause and progression of ALS using the patented viral gene delivery platform SVac. Treeway and Amarna Therapeutics ultimately hope to develop a reverse vaccine to stop disease progression of ALS.
Ben van Leent, CEO of Amarna said, "After developing our SVac gene delivery platform, we are excited to enter the area of high unmet diseases like ALS. We are convinced that the combination of the expertise of Treeway, Amarna Therapeutics and our research partner CABIMER in Seville will lead to the development of breakthrough solutions for ALS."